Brevan Howard Capital Management’s Precision BioSciences DTIL Stock Holding History

Brevan Howard Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$189K	Buy	+34,442	New	+$159K	﹤0.01%	1913

Other funds holding DTIL

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Empery Asset Management New York $83M AUM

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Brevan Howard Capital Management's DTIL Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Precision BioSciences (DTIL) in Q1 2026: 34,442 shares worth $189K. The stake represents ﹤0.01% of the portfolio and ranks #1913 among its holdings.

78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

Brevan Howard Capital Management held 34,442 shares of Precision BioSciences worth $189K as of Q1 2026.
Precision BioSciences was a new Brevan Howard Capital Management position in Q1 2026.
Precision BioSciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1913 holding.
78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.